Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 2, 2008, Pages 102-108

  Séchaud, Romain ^a   Dutreix, C ^a   Balez, S ^b   Pommier, F ^b   Dumortier, T ^a   Morisson, S ^b   Brun, E ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Apple juice; Deferasirox; Degree of tablet dispersion; Orange juice; Relative bioavailability

Indexed keywords

DEFERASIROX; IRON; WATER;

APPLE JUICE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CARBONATED BEVERAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MILK; NORMAL HUMAN; OPEN STUDY; ORANGE JUICE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET;

EID: 39049093099     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46102     Document Type: Article

References (15)

1. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006; 107: 3455-3462.
2. Chun AH, Erdman K, Chiu YL, Pilmer BL, Achari R, Cavanaugh JH. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation. Clin Ther. 2002; 24: 1322-1331.
3. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest. 2003; (33 Suppl 2): 10-16.
4. Galanello R, Piga A, Alberti D. Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003; 43: 565-572.
5. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003; 42: 1071-1088.
6. Kovarik JM, Mueller EA, Johnston A, Hitzenberger G, Kutz K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy. 1993; 13: 613-617.
7. Kovarik JM, Barilla D, McMahon L, Wang Y Kisicki J, Schmouder R. Administration diluents differentiate Neoral from a generic cyclosporine oral solution. Clin Transplant. 2002; 16: 306-309.
8. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006; 107: 3436-3441.
9. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP. ICL670A: preclinical profile. Adv Exp Med Biol. 2002; 509: 185-203.
10. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003; 361: 1597-1602.
11. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother. 2001; 35: 1332-1338.
12. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; 91: 873-880.
13. Porter JB. Practical management of iron overload. Br J Haematol. 2001; 115: 239-252.
14. Porter JB. Deferasirox: An effective once-daily orally active iron chelator. Drugs Today. 2006; 42: 623-637.
15. VanOrden HE, Hagemann TM. Deferasirox - an oral agent for chronic iron overload. Ann Pharmacother. 2006; 40: 1110-1117.